| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $117.0M | -33.4% |
| SG&A Expense | $31.4M | -2.4% |
| Operating Income | -$148.4M | +28.6% |
| Pre-tax Income | -$135.1M | +30.0% |
| Net Income | -$135.1M | +30.0% |
| EPS (Basic) | -$1.97 | +40.3% |
| EPS (Diluted) | -$1.97 | +40.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $27.3M | -47.1% |
| Short-term Investments | $190.1M | -5.3% |
| Current Assets | $229.6M | -13.1% |
| Total Assets | $276.6M | -0.4% |
| Current Liabilities | $12.8M | -42.6% |
| Total Liabilities | $22.5M | -33.3% |
| Stockholders' Equity | $254.0M | +4.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$130.9M | +21.4% |
| Capital Expenditures | $241K | -53.1% |
| Investing Cash Flow | -$15.5M | -115.4% |
| Financing Cash Flow | $122.1M | +129.0% |
| Free Cash Flow | -$131.1M | +21.5% |